We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Microalbuminuria Predicts Renal Disease in Hypertension

By LabMedica International staff writers
Posted on 20 Jul 2010
The level of a protein found in urine samples, when compared to the amount of creatinine excreted, is a powerful predictor of long-term development of chronic renal insufficiency (CRI).

Increased urinary albumin is a risk factor for cardiovascular events and clinical nephropathy in patients with diabetes. More...
The urinary albumin to creatinine ratio (ACR) is used to assess the increased probability of clinical nephropathy.

In a study, conducted by Italian scientists, 917 patients who did not have diabetes but had hypertension were enrolled in the investigation and followed-up for 11.7 years. Their urine was assayed for albumin (microalbuminuria) and creatinine and the ratio calculated. Microalbuminuria occurs when the kidney leaks small amounts of albumin into the urine, in other words, when there is an abnormally high permeability for albumin in the renal glomerulus. Microalbuminuria was defined as ACR ≥ 22 mg/g in men and ACR as ≥ 31 mg/g in women.

The follow-up revealed that baseline microalbuminuria was associated with an increased risk for developing CRI; cardiovascular events, both fatal and nonfatal cardiac and cerebrovascular events; and cardiorenal events. Microalbuminuria remained significantly related to CRI and cardiorenal events even after adjustment for several baseline covariates.

The senior author on the study, Roberto Pontremoli, M.D., Ph.D., from the University of Genoa (Genoa, Italy) said. "Our findings emphasize the usefulness of a more widespread evaluation of microalbuminuria in an effort to guide the management of hypertension.” Microalbuminuria is an independent predictor of renal and cardiovascular complications in patients without diabetes and with primary hypertension.

The scientists conclude that patients with microalbuminuria should be aggressively targeted for renal and cardiovascular risk factor reduction, although further investigation is warranted to determine whether specific treatment would help to improve outcomes, as already reported for patients with diabetes. The study was reported online in April 2010 in the Clinical Journal of the American Society of Nephrology (CJASN).

Related Links:

University of Genoa




Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Clinical Chemistry System
P780
ESR Analyzer
TEST1 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: The initiative aims to speed next-generation diagnostic development during early pathogen emergence (photo courtesy of 123RF)

Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss

Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.